查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球急性激动和攻击性治疗市场 - 2022-2029
市场调查报告书
商品编码
1140681

全球急性激动和攻击性治疗市场 - 2022-2029

Global Acute Agitation and Aggression Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

老年人口中痴呆症发病率的增加支持了预测期内市场的增长。

痴呆症和抑郁症是最常见的精神和神经系统疾病之一。痴呆症影响全球约 5% 的老年人口，抑郁症影响约 7%。目前，临床试验正在进行中，以利用这种药物的特性为其他健康问题提供有效的治疗，例如与阿尔茨海默病相关的躁动和 PTSD。成年人通常不遵守并且能够克服与治疗精神障碍相关的社会污名。他们比老年人更有可能被诊断出患有精神疾病并接受治疗。

此外，工作压力的增加正在推动全球市场的增长。急性激动和攻击性的一个主要驱动因素是工作压力增加。工作场所的压力可能来自多种来源，也可能来自单一事件。它也可能影响雇主和僱员。根据美国国家心理健康研究所的数据，到 2020 年，美国将有 5290 万 18 岁及以上的成年人患上 AMI。这个数字占美国所有成年人的 21.0%。发现某种形式的精神疾病在女性中的患病率（25.8%）高于男性（15.8%）。与 26-49 岁 (25.3%) 和 50 岁及以上 (14.5%) 的人相比，18-25 岁的年轻人的 AMI 患病率也最高 (30.6%)。此外，据报导，美国的压力增加。例如，根据美国压力协会 (AIS) 的数据，各种研究表明，工作压力是美国成年人压力的主要原因，并且这种趋势在过去十年中有所增加。

地理渗透

北美在整个预测期内引领全球市场。

北美在急性激动和攻击性治疗市场的全球市场中占主导地位，预计在预测期内将保持其地位。美国在北美急性激越和攻击性治疗市场的市场份额最高。完善的医疗基础设施，包括完善的心理健康机构和结构，支持急性躁动和攻击性治疗市场。此外，Pfizer Inc., Janssen Biotech, Inc., Eli Lilly Company等主要参与者正在进一步推动该地区的市场增长。

据估计，在预测期内，亚太地区的急性激动和攻击性治疗市场将以可观的增长率增长。鑑于亚太地区政府为建立非正规医疗基础设施投入了大量资金，这一增长可归因于该地区市场参与者的扩张。

竞争格局。

急性激动和攻击性治疗市场是一个竞争激烈的市场。为全球市场增长做出贡献的领先急性激动和攻击製造商包括Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals和Pfizer Inc. 。领先公司正在为急性激动和攻击性治疗市场的全球增长采用新产品发布和扩张战略。2022 年 7 月，Impel Pharmaceuticals 宣布了第 2a 期患者剂量，该剂量评估 INP105，专门用于治疗患有自闭症谱系障碍的青少年的急性躁动。INP105 专为治疗自闭症谱系障碍 (ASD) 患者的急性焦虑症而开发，通过 Impel 专有的 POD（精确嗅觉递送）技术将药物输送到上鼻道。这一剂量的结果预计在 2023 年第一季度。同样在 2022 年 4 月，BioXcel Therapeutics 宣布其 IGALMI（右美托咪定）舌下薄膜已获得 FDA 批准，用于“急性治疗与成人精神分裂症或双相 I 型障碍相关的激越”。该批准包括两项关键、随机、双盲、安慰剂对照、平行组研究，评估右美托咪定用于急性治疗与精神分裂症或双相 I 或 II 障碍相关的激越。它主要是根据 3 期试验的数据确定的.

COVID-19 的影响将对全球急性激越和攻击性治疗市场产生负面影响。

COVID-19 的爆发无疑影响了全球急性躁动和攻击性治疗市场，因为它迫使患者诊断和门诊就诊。随着研究人员转向开发 COVID-19 疫苗，治疗急性躁动和攻击性药物的研究和开发受到限制。因此，预计 2020 年急性激越和攻击性治疗市场将显着下降。

该报告提供了大约 61 个市场数据表、52 个数字和 170 页有关全球急性激越和攻击性治疗市场的信息。

目录

第一章 调查方法和范围

  • 调查方法
  • 市场范围

第二章主要趋势和发展

第三章执行摘要

  • 按药物类别划分的市场细分
  • 按管理途径划分的市场细分
  • 最终用户的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
    • 抑製剂
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措

第 7 章 按药物类别

  • 抗精神病药
  • 苯二氮卓类
  • 其他

第八章 行政途径

  • 口服
  • 肌肉注射
  • 其他

第 9 章最终用户

  • 医院/门诊手术中心
  • 精神病院
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 11 章按药物类别的市场规模分析，同比增长分析 (%)，按药物类别

12. 市场规模分析和同比增长分析（%）：按管理途径

13. 最终用户的市场规模分析和同比增长分析 (%)

第十四章 竞争格局

  • 竞争情景
  • 竞争对手战略分析
  • 市场/份额分析
  • 併购分析

第十五章公司简介

  • Bristol-Myers Squibb Company
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Janssen Biotech, Inc.（Johnson & Johnson）
  • Ono Pharmaceutical Co., Ltd.
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd

第 16 章 数据管理

简介目录
Product Code: DMHCIT2973

Market Overview

Acute Agitation and Aggression Treatment Market are expected to grow at a CAGR of 5% during the forecasting period (2022-2029).

Agitation is characterized as excessive verbal or motor behavior in an individual. It can lead to aggression, which can be either verbal or physical. Several treatment options are available for managing acute agitation and aggression, including environmental de-escalation strategies and biological treatment options and non-pharmacologic behavioral, such as electroconvulsive therapy and pharmacologic agents. The rising prevalence of acute agitation and aggression due to workplace stress and the rising burden of mental illness are some factors that are expected to propel market growth. Moreover, the government awareness programs and increasing incidence of dementia in the geriatric population are further supporting the development of the market across the globe.

Market Dynamics: An increase in the incidence of dementia in the geriatric population continues supporting the market's growth during the forecast period.

Dementia and depression are some of the most prevalent mental and neurological disorders. Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Moreover, increasing workplace stress is driving the growth of the global market. A major driving factor for acute agitation and aggression is increasing workplace stress. Workplace stress can have a lot of origins or come from a single event. It can affect employees as well as employers alike. According to the National Institute of Mental Health, in 2020, an estimated 52.9 million adults aged 18 or older than this in the United States with AMI. This number represented 21.0% of all U.S. adults. This prevalence of any mental illness was higher in females (25.8%) than males (15.8%). Young adults aged 18-25 years had the highest prevalence of AMI (30.6%) compared to adults aged 26-49 years (25.3%) and aged 50 and older (14.5%). Also, an increased level of stress was reported in the U.S. For instance, as per the American Institute of Stress (AIS), various studies demonstrated that job stress is a major reason for the stress among adults in the U.S., which has intensified in the last decade.

Market Segmentation: The anti-psychotics segment accounted for the highest share in global acute agitation and aggression treatment market.

Dementia and depression are some of the most prevalent mental and neurological disorders. According to World Health Organization, Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Based on the route of administration, the acute agitation and aggression treatment market have been bifurcated into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in forecast period. In the acute agitation and aggression treatment market, the major route of administration is an oral treatment. Several drugs are offered by the key market players taken orally to treat acute agitation and aggression. The lack of awareness of the intramuscular treatment solutions for acute agitation and aggression further contributes to the rise in the adoption of oral treatment solutions. The intramuscular administration route is generally preferred to the subcutaneous route, especially when larger drug solutions are needed. Moreover, a longer needle is required for the intramuscular route, limiting its adoption and supporting the growth of the oral route of administration to treat acute agitation and aggression.

Geographical Penetration: North America leads the global market throughout the forecast period.

North America dominated the global acute agitation and aggression treatment market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American acute agitation and aggression treatment market. The well-developed healthcare infrastructure, including the established mental health institutions and mental health structure, supports its acute agitation and aggression treatment market. Moreover, some of the key players, such as Pfizer Inc., Janssen Biotech, Inc., and Eli Lilly and Company, are further driving the market's growth in the region.

The Asia Pacific is estimated to grow at a considerable growth rate in the acute agitation and aggression treatment market during the forecast period. This growth can be accredited to the expansion of market players in the region, considering the high investment for establishing informal healthcare infrastructure by the governments in the Asia Pacific.

Competitive Landscape:

The acute agitation and aggression treatment market is highly competitive. The key acute agitation and aggression treatment players contributing to the global market's growth include Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals and Pfizer Inc. The major players are adopting new product launches and expansion strategies for global growth in the acute agitation and aggression treatment market. In July 2022, Impel Pharmaceuticals Announced First Patient Dosed in Phase 2a Evaluating INP105 especially to Treat Acute Agitation in Adolescents with Autism Spectrum Disorder. INP105 is specially developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) by using Impel's proprietary Precision Olfactory Delivery (POD) technology that delivers drugs to the upper nasal space. Results of this dose are expected in Q1 2023. Also, in April 2022, BioXcel Therapeutics Announced that they got FDA Approval for IGALMI (dexmedetomidine) Sublingual Film, which is used in Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults. This approval is generally based on data from two pivotal randomized, double-blinded, placebo-controlled, parallel-group Phase 3 trials evaluating dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

COVID-19 Impact: Negative impact on the global acute agitation and aggression treatment market.

The outbreak of COVID-19 has certainly impacted the global acute agitation and aggression treatment market, as the lockdown has compelled the diagnosis and the clinic visits of patients. The researchers' shift towards developing the COVID-19 vaccine has deterred the R&D in acute agitation and aggression treatment. Therefore, the acute agitation and aggression treatment market are expected to foresee a considerable decline in 2020.

The global acute agitation and aggression treatment market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by End Users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Class Segment
    • 7.1.2. Market attractiveness index, By Drug Class Segment
  • 7.2. Anti-Psychotics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Benzodiazepines
  • 7.4. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Route of Administration Segment
    • 8.1.2. Market attractiveness index, By Route of Administration Segment
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Intramuscular
  • 8.4. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By End Users Segment
    • 9.1.2. Market attractiveness index, By End Users Segment
  • 9.2. Hospitals & Ambulatory Surgical Centers *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Psychiatric Care Facilities
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
      • 10.2.2.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      • 10.2.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
      • 10.2.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
      • 10.2.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.2.5. U.S.
      • 10.2.2.6. Canada
      • 10.2.2.7. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.7.1. Brazil
      • 10.3.7.2. Argentina
      • 10.3.7.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.7.1. Germany
      • 10.4.7.2. U.K.
      • 10.4.7.3. France
      • 10.4.7.4. Spain
      • 10.4.7.5. Italy
      • 10.4.7.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics

11. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

12. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

13. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

14. Competitive Landscape

  • 14.1. Competitive scenario
  • 14.2. Competitor strategy analysis
  • 14.3. Market positioning/share analysis
  • 14.4. Mergers and acquisitions analysis

15. Company Profiles

  • 15.1. Bristol-Myers Squibb Company*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Key Highlights
    • 15.1.4. Financial Overview
  • 15.2. Eli Lilly and Company
  • 15.3. GlaxoSmithKline plc
  • 15.4. H. Lundbeck A/S
  • 15.5. Janssen Biotech, Inc. (Johnson & Johnson)
  • 15.6. Ono Pharmaceutical Co., Ltd.
  • 15.7. Otsuka Holdings Co., Ltd.
  • 15.8. Pfizer Inc.
  • 15.9. Mylan NV
  • 15.10. Teva Pharmaceutical Industries Ltd
  • List not Exhaustive*

16. DataM

  • 16.1. Appendix
  • 16.2. About us and services
  • 16.3. Contact us